Back to search
FDAFDA · Food and drugs·Recall number D-0013-2027

Lidocaine Ointment USP, 5% (Generic for Xylocaine), packaged in a 50 g jar, Rx only, Mfg: Taro Pharmaceuticals U.S.A., Inc., Prod# (NDC): 68788-7865-05

Published October 14, 2026 · Recall initiated: September 28, 2026

Summary

FDA records drug Class II recall D-0013-2027, published October 14, 2026 and initiated September 28, 2026. Recalling firm: Preferred Pharmaceuticals, Inc.; Status: Ongoing; Reported quantity: N/A; Lot: Lot #: F1925G, Expiry: 4/30/2027; Lot #: E0925T, Expiry: 4/30/2027; Lot # D3025M, Expiry: 4/30/2027; Lot #: D0825D, Expiry: 4/30/2027. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Content Uniformity Specifications

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Preferred Pharmaceuticals, Inc.
Distributor
USA Nationwide
Lot
Lot #: F1925G, Expiry: 4/30/2027; Lot #: E0925T, Expiry: 4/30/2027; Lot # D3025M, Expiry: 4/30/2027; Lot #: D0825D, Expiry: 4/30/2027.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Lidocaine Ointment USP, 5% (Generic for Xylocaine), packaged in a 50 g jar, Rx only, Mfg: Taro Pharmaceuticals U.S.A., Inc., Prod# (NDC): 68788-7865-05 recalled?

Yes. FDA published recall D-0013-2027 on October 14, 2026. Reported hazard: Failed Content Uniformity Specifications

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail